Targets for Polycythemia Vera

Polycythemia Vera (PV) is a myeloproliferative neoplasm characterized by excessive erythrocyte production, most commonly driven by acquired mutations that dysregulate key signaling pathways involved in hematopoiesis. Understanding the molecular targets implicated in PV pathogenesis is essential for elucidating disease mechanisms, identifying actionable therapeutic nodes, and guiding rational drug development. Among the targets listed, only a subset are directly implicated in PV: Janus kinase 2 (JAK2), Janus kinase 1 (JAK1), tyrosine kinase 2 (TYK2), and KIT proto-oncogene (KIT), as well as Hepcidin Antimicrobial Peptide (HAMP) and Solute Carrier Family 40 Member 1 (SLC40A1), which are crucial for iron metabolism and erythropoiesis. The JAK-STAT pathway—especially the JAK2 V617F mutation—constitutes the central molecular driver in PV, conferring cytokine-independent proliferation and survival of erythroid progenitors. Dysregulation of KIT signaling and iron homeostasis (HAMP, SLC40A1) further modulate erythropoiesis and disease phenotype. These insights have enabled the development of targeted kinase inhibitors (e.g., ruxolitinib for JAK2) and inform ongoing research into iron metabolism modulators and KIT inhibitors. Collectively, these targets provide a mechanistic framework for understanding PV pathogenesis, identifying biomarkers, and supporting the development of precision therapies.

Jak-Stat Pathway Dysregulation

This category includes targets directly involved in the JAK-STAT signaling cascade, which is central to the pathogenesis of Polycythemia Vera due to the high prevalence of activating mutations (notably JAK2 V617F). These mutations result in constitutive activation of downstream signaling, promoting uncontrolled erythroid proliferation. Only JAK2, JAK1, and TYK2 are included here, as they are directly implicated in the disease mechanism.

Janus Kinase 2 (JAK2)

Janus Kinase 2 (JAK2) is a non-receptor tyrosine kinase characterized by a FERM domain, SH2-like domain, pseudokinase (JH2), and kinase (JH1) domains. JAK2 is tightly regulated by autoinhibition and phosphorylation. Mutations, particularly V617F in the JH2 domain, disrupt autoinhibition, leading to constitutive activation. JAK2 is central to cytokine receptor signaling (EPO, TPO, GM-CSF), mediating STAT activation and transcription of proliferation/survival genes. In PV, >95% of cases harbor JAK2 V617F, causing cytokine-independent erythroid proliferation. This mutation is sufficient to recapitulate PV in mouse models and is a validated driver mutation. JAK2 inhibitors (e.g., ruxolitinib) are approved for PV, demonstrating clinical benefit by reducing hematocrit and symptom burden. JAK2 V617F also serves as a diagnostic and minimal residual disease biomarker. (Entrez: 3717, KEGG: 3717, UniProt: O60674)

Janus Kinase 1 (JAK1)

Janus Kinase 1 (JAK1) is a non-receptor tyrosine kinase with FERM, SH2-like, pseudokinase, and kinase domains. JAK1 partners with other JAKs to mediate cytokine receptor signaling, especially for interferons and interleukins. While JAK1 mutations are not primary drivers in PV, JAK1 is required for full JAK2-mediated signaling and contributes to disease phenotype. JAK1 is a target of pan-JAK inhibitors and may modulate inflammatory cytokine responses in PV. (Entrez: 3716, KEGG: 3716, UniProt: P23458)

Tyrosine Kinase 2 (TYK2)

Tyrosine Kinase 2 (TYK2) is a member of the JAK family, with similar structural domains as JAK2. TYK2 primarily mediates type I interferon and interleukin-12/23 signaling. While not mutated in PV, TYK2 can interact with JAK2 in cytokine signaling complexes, potentially modulating disease-related inflammation and immune responses. TYK2 is a secondary target of some JAK inhibitors. (Entrez: 7297, KEGG: 7297, UniProt: P29597)

Receptor Tyrosine Kinase Pathway

This category includes receptor tyrosine kinases directly implicated in the regulation of hematopoiesis and erythroid progenitor proliferation in Polycythemia Vera. KIT is the only target from the list with a direct mechanistic role in PV.

KIT Proto-Oncogene, Receptor Tyrosine Kinase (KIT)

KIT is a type III receptor tyrosine kinase with five extracellular immunoglobulin-like domains, a transmembrane domain, and split cytoplasmic kinase domains. KIT is activated by stem cell factor (SCF) binding, leading to receptor dimerization, autophosphorylation, and downstream signaling via PI3K/AKT, MAPK, and JAK/STAT pathways. KIT is essential for hematopoietic stem cell survival and proliferation. Although activating KIT mutations are rare in PV, aberrant KIT signaling cooperates with JAK2 in erythroid expansion. KIT is a target for tyrosine kinase inhibitors (e.g., imatinib), though their efficacy in PV is limited. KIT expression and signaling may contribute to disease phenotype and resistance. (Entrez: 3815, KEGG: 3815, UniProt: P10721; A0A8I5KS03)

Iron Homeostasis And Erythropoiesis Regulation

This category includes targets that regulate systemic iron homeostasis and erythropoiesis. Hepcidin (HAMP) and the iron exporter ferroportin (SLC40A1) are directly involved in the control of iron availability for erythropoiesis, which is pathologically altered in PV.

Hepcidin Antimicrobial Peptide (HAMP)

Hepcidin (HAMP) is a 25-amino-acid peptide hormone produced by the liver, featuring a β-sheet structure stabilized by disulfide bonds. Hepcidin binds to and induces internalization/degradation of ferroportin (SLC40A1), the only known cellular iron exporter. In PV, erythroid expansion suppresses hepcidin, increasing iron availability for erythropoiesis and sustaining erythrocytosis. Hepcidin levels inversely correlate with erythropoietic drive and are being explored as biomarkers of marrow activity and iron-restricted erythropoiesis. Modulation of hepcidin is under investigation as a therapeutic approach to limit iron availability and control erythrocytosis in PV. (Entrez: 57817, KEGG: 57817, UniProt: P81172)

Solute Carrier Family 40 Member 1 (SLC40A1)

Solute Carrier Family 40 Member 1 (SLC40A1), also known as ferroportin, is a transmembrane iron exporter with 12 predicted transmembrane domains. Ferroportin is regulated by hepcidin binding, which triggers its internalization and degradation. In PV, increased erythropoiesis suppresses hepcidin, leading to increased ferroportin activity and systemic iron mobilization. This supports the high erythroid output characteristic of PV. Ferroportin is a potential therapeutic target for controlling iron availability and erythrocyte production in PV. (Entrez: 30061, KEGG: 30061, UniProt: Q9NP59)